AKTX - Company ID 0001541157
The table below shows Akari Therapeutics Plc's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $1.46M | $249.00K | $667.00K | $813.00K | $143.00K | $3.31M |
| SG&A |
Akari Therapeutics Plc reported annual revenue of $367.88K for fiscal year 2023. That is down 39.5% from $607.68K in fiscal 2022. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.17M |
| $1.98M |
| $2.45M |
| $2.71M |
| $1.71M |
| $2.24M |
| Operating income | -$15.76M | -$7.40M | -$3.12M | -$3.52M | -$2.93M | -$7.45M |
| Income tax | -$859.00K | -$1.09M | $0.00 | $0.00 | - | $0.00 |
| Net income | -$14.46M | -$6.40M | -$1.90M | -$3.71M | -$2.90M | -$7.56M |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |